Sarepta's 15-Min Chart Shows MACD and KDJ Death Crosses

Based on the 15-minute chart for Sarepta, a technical indicator analysis reveals that the Moving Average Convergence Divergence (MACD) has triggered a "death cross," while the KDJ indicator has also triggered a "death cross" at 08/08/2025 15:15. These indicators suggest that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.

Title: Sarepta Therapeutics: Analysts Raise Price Target Amid Mixed Market Sentiment

Wells Fargo (NYSE:WFC) has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $50.00 from $48.00, maintaining an Overweight rating on the stock. The move comes amidst mixed market sentiment, with analyst targets ranging from $5 to $80 [1]. Despite the recent price drop of over 85% in the past six months, Sarepta's stock is currently trading significantly below its Fair Value.

The firm's decision is based on progress across Sarepta’s siRNA programs developed in partnership with Arrowhead Pharmaceuticals (NASDAQ:ARWR). The SRP-1001 Phase 1/2 study for facioscapulohumeral muscular dystrophy (FSHD) has fully enrolled three single ascending dose cohorts, with preliminary data expected in the second half of 2025. Similarly, the SRP-1003 program targeting myotonic dystrophy type 1 (DM1) and the SRP-1004 program for spinocerebellar ataxia type 2 (SCA2) have also made significant strides, with the latter's first cohort fully enrolled in the Phase 1 study [1].

Sarepta also plans to file a Clinical Trial Application for SRP-1005, its Huntington’s disease candidate, by the end of 2025, with clinical study initiation targeted for the first half of 2026. Additionally, the company reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings of $2.02 per share, far surpassing the analyst consensus of $0.70 [1].

Technically, the 15-minute chart for Sarepta indicates a "death cross" in both the MACD and KDJ indicators on August 8, 2025, at 15:15. This suggests a potential continuation of the stock's downward trend, with the momentum shifting towards the downside [2].

While the company's strong financial performance and operational progress are encouraging, the mixed market sentiment and technical indicators suggest caution for investors. Sarepta's stock has the potential to continue declining, making it essential for investors to closely monitor the company's clinical developments and market dynamics.

References:
[1] https://za.investing.com/news/analyst-ratings/sarepta-therapeutics-stock-price-target-raised-to-50-by-wells-fargo-93CH-3825247
[2] https://www.barchart.com/story/news/34000747/duchenne-muscular-dystrophy-market-set-to-grow-substantially-through-2034-delveinsight-projects-sarepta-therapeutics-santhera-pharma-reveragen-biopharma-pfizer-fibrogen-capricor-therapeutics